Divi's Laboratories Limited has reported a 17% rise in consolidated net profit to ₹2,568 crore for the financial year ended March 31, 2026, compared to ₹2,191 crore in the previous year. The company’s consolidated total income for FY26 reached ₹11,067 crore, up from ₹9,712 crore in FY25, driven by operational growth and a forex gain of ₹211 crore. The Board has recommended a final dividend of ₹30 per share, subject to shareholder approval.

Financial Performance

Profit before tax (PBT) for the year stood at ₹3,388 crore. The financial results include an exceptional item of ₹74 crore related to the impact of new Labour Codes. On a standalone basis, the company reported a net profit of ₹2,607 crore for FY26, with a total income of ₹10,894 crore.

Operational Highlights

Exports contributed nearly 89% of the total sales revenue, with Europe and the United States together accounting for approximately 74% of the export revenue. The product mix between generics and custom synthesis for the year was 45% and 55%, respectively. Constant currency growth for the year was 6.82%. Revenue from the nutraceuticals business for the current financial year amounted to ₹946 crore compared to ₹781 crore in the previous financial year.

Material consumption during the current financial year stood at approximately 38.8% of sales revenue compared to 39.8% in the previous year. During the year, the company capitalized assets worth ₹1,544 crore. Capital work in progress as of March 31, 2026, stood at ₹2,113 crore. As on March 31, 2026, the company's cash and cash equivalents stood at ₹3,414 crore, receivables at ₹2,984 crore, and inventories at ₹3,954 crore.

Dividend Declaration

The Board of Directors recommended a final dividend of ₹30 per equity share of face value ₹2 each, translating to 1,500% for FY26. The record date for determining dividend eligibility is fixed as July 24, 2026. The dividend requires approval at the ensuing 36th Annual General Meeting.

Divi's Laboratories Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, in accordance with SEBI regulatory requirements. The pharmaceutical company filed the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Submission

The compliance certificate was submitted to both major Indian stock exchanges where the company's shares are listed. Company Secretary & Compliance Officer M. Satish Choudhury signed and submitted the documentation on April 06, 2026.

Certificate Confirmation Details

KFin Technologies Limited, serving as the Registrar & Share Transfer Agent, provided confirmation regarding the dematerialization process for the quarter. Deputy Vice President Ganesh Chandra Patro signed the certificate on April 02, 2026, confirming compliance with regulatory requirements.

The certificate confirms several key operational aspects:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities have been listed on BSE Limited and National Stock Exchange of India Limited
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members within the mandated 15-day period

Stock Exchange Communication

The submission was made to both primary stock exchanges where Divi's Laboratories shares are traded. The company maintains its listing on National Stock Exchange of India Limited and BSE Limited, ensuring compliance across all trading platforms.

This quarterly submission represents standard regulatory compliance for listed companies, ensuring transparency in securities handling and depository operations. The certificate validates that all dematerialization processes during the quarter were conducted in accordance with SEBI guidelines and exchange requirements.